RT Journal Article
T1 Evidence for Sodium Azide as an Artifact Mediating the Modulation of Inducible Nitric Oxide Synthase by C-Reactive Protein
A1 Lafuente, Nuria
A1 Azcutia Criado, Verónica
A1 Matesanz, Nuria
A1 Cercas, Elena
A1 Rodríguez-Mañas, Leocadio
A1 Sánchez-Ferrer, Carlos F.
A1 Peiró, Concepción
AB C-reactive protein (CRP) is an acute-phase protein identified as a cardiovascular risk marker. In recent years, an increasing number of studies have investigated the possible direct effects of CRP on the vasculature, using mainly commercial CRP. In the present work, a potential role for CRP as a modulator of inducible nitric oxide synthase (iNOS) induction was explored. Cultured human aortic vascular smooth muscle cells (HASMC) were stimulated for 18 hours with 10 ng/mL interleukin-1beta (IL-1b), resulting in a marked increase of iNOS levels and NO production, as determined by Western blotting and nitrite measurement, respectively. Commercial CRP (1 to 100 mg/mL) concentration-dependently inhibited the effects elicited by IL-1b. Unexpectedly, similar results were observed when the commercial CRP solution was replaced by the corresponding vehicle medium containing growing concentrations of sodium azide. The inhibitory effects of commercial CRP or vehicle medium were lost on sodium azide removal by dialysis. In conclusion, sodium azide from the commercial CRP solution, but not CRP itself, mainly accounts for the inhibitory effect on IL-1b-evoked iNOS induction and NO release. Care should be taken before attributing any biologic role to commercial CRP containing sodium azide.
PB Lippincott Williams & Wilkins
SN 0160-2446
YR 2005
FD 2005
LK https://hdl.handle.net/20.500.14352/100975
UL https://hdl.handle.net/20.500.14352/100975
LA eng
NO Lafuente N, Azcutia V, Matesanz N, Cercas E, Rodríguez-Mañas L, Sánchez-Ferrer CF, et al. Evidence for Sodium Azide as an Artifact Mediating the Modulation of Inducible Nitric Oxide Synthase by C-Reactive Protein. Journal of Cardiovascular Pharmacology 2005;45:193–6. https://doi.org/10.1097/01.fjc.0000154371.95907.bd.
NO Ministerio de Ciencia y Tecnología (España)
NO Comunidad de Madrid 
NO Instituto de Salud Carlos III
DS Docta Complutense
RD 23 ene 2026